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Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) is the principal oncogenic protein in the EBV
transformation process. LMP-1 induces the expression of interferon regulatory factor 7 (IRF-7) and activates
IRF-7 protein by phosphorylation and nuclear translocation. LMP-1 is an integral membrane protein with two
regions in its C terminus that initiate signaling processes, the C-terminal activator regions 1 (CTAR-1) and
CTAR-2. Here, genetic analysis of LMP-1 has determined that the PXQXT motif that governs the interaction
between LMP-1 CTAR-1 and tumor necrosis factor receptor-associated factors (TRAFs) is needed to induce the
expression of IRF-7. Mutations in the PXQXT motif in CTAR-1 that disrupt the interaction between LMP-1
and TRAFs abolished the induction of IRF-7. Also, dominant-negative mutants of TRAFs inhibited the
induction of IRF-7 by CTAR-1. The last three amino acids (YYD) of CTAR-2 are also important for the
induction of IRF-7. When both PXQXT and YYD were mutated (LMP-DM), the LMP-1 mutant failed to induce
IRF-7. Also, LMP-DM blocked the induction of IRF-7 by wild-type LMP-1. These data strongly suggest that
both CTAR-1 and CTAR-2 of LMP-1 independently induce the expression of IRF-7. In addition, NF-B is
involved in the induction of IRF-7. A superrepressor of IB (sr-IB) could block the induction of IRF-7 by
LMP-1, and overexpression of NF-B (p65 plus p50) could induce the expression of IRF-7. In addition, we have
found that human IRF-7 is a stable protein, and sodium butyrate, a modifier of chromatin structure, induces
IRF-7.
Epstein-Barr virus (EBV) is a human herpesvirus of increas-
ing medical importance. EBV infection is associated with the
development of nasopharyngeal carcinoma and Burkitt’s lym-
phoma (BL). In addition, EBV infection is an important cause
of lymphomas in severely immunocompromised persons, espe-
cially patients with AIDS and organ transplant recipients (24,
36–38, 40). In vitro, EBV efficiently infects and immortalizes
primary B-lymphocytes, and latent membrane protein 1
(LMP-1) expression is required for this immortalization pro-
cess (22, 26). LMP-1 can induce a variety of cellular genes that
enhance cell survival (13, 17, 32, 44) and adhesive (45), inva-
sive, and angiogenic potential (35, 48).
LMP-1 is an integral membrane protein with six transmem-
brane-spanning domains and a long C-terminal domain, which
is located in the cytoplasm (24, 28). LMP-1 acts as a constitu-
tively active receptor-like molecule that does not need the
binding of a ligand (16). The six transmembrane domains me-
diate oligomerization of LMP-1 molecules in the plasma mem-
brane, a prerequisite for LMP-1 function (12, 16). Roughly,
two regions in the C terminus of LMP-1 have been shown to
initiate signaling processes, the C-terminal activator regions 1
(CTAR-1) (amino acids 194 to 231) and CTAR-2 (amino acids
332 to 386) (Fig. 1) (18, 34).
CTAR-1 is a minor contributor to the activation of nuclear
factor B (NF-B) by LMP-1 (about 25%). The PXQXT motif
localized within CTAR-1 is involved in the interaction with
tumor necrosis factor receptor-associated factors (TRAFs).
TRAF1, -2, -3, and -5 associate with LMP-1 with different
affinities and are responsible for NF-B activation by CTAR-1
(6, 7, 33, 41). CTAR-1 is responsible for induction of epider-
mal growth factor receptor and TRAF1 (7, 33). CTAR-1 is
required for the transformation of B cells by EBV, and the
PXQXT motif is essential for this process (20, 23).
CTAR-2 is a major contributor to the activation of NF-B by
LMP-1 (about 75%). CTAR-2, through its interaction with
tumor necrosis factor receptor-associated death domain pro-
tein (TRADD), activates NF-B (19, 21). Also, c-jun N-termi-
nal kinase (JNK) and p38 are activated by CTAR-2 (9, 10, 25).
The last three amino acids (YYD) of CTAR-2 have been
shown to play an essential role in the activation of NF-B.
Recently, two Janus kinase 3 (JAK-3) binding sites have
been identified, which are located between CTAR-1 and
CTAR-2 (Fig. 1). JAK-3 can bind to these sites and is respon-
sible for the activation of signal transducer and activator of
transcription 1 (STAT-1) (15).
Interferon regulatory factor 7 (IRF-7) was first cloned by its
binding activity to the EBV BamHI Q promoter (Qp) used in
latently infected EBV infection for transcription of EBNA-1,
and it has subsequently been implicated as a negative regulator
of the type I latency promoter, Qp (50, 51, 53). IRF-7 is also
involved in the activation of cellular Tap-2 and interferon
(IFN) genes (1, 30, 47, 52).
LMP-1 has a strong relation with IRF-7. LMP-1 regulates
IRF-7 in three ways: (i) induction of the expression of IRF-7,
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(ii) initiation of the phosphorylation of IRF-7, and (iii) facili-
tation of the nuclear translocation of IRF-7 (51, 52). However,
how LMP-1 induces IRF-7 is completely unknown. In this
report, the experiments were designed to determine the con-
tributions of various signaling molecules involved in the induc-
tion of IRF-7 by LMP-1. The genetic analysis of LMP-1 has
identified both CTAR-1 and CTAR-2 as independently induc-
ing the expression of IRF-7. In addition, TRAFs and NF-B
are involved in the induction of IRF-7.
MATERIALS AND METHODS
Cells, plasmids, and antibodies. DG75 is an EBV-negative BL cell line (2).
Jijoye is an EBV-positive BL line with type III latency (39). Cells were main-
tained in RPMI-1640 plus 10% fetal bovine serum. pcDNA/CD4 is a human CD4
expression plasmid (gift of Jenny Ting). The LMP-1 expression plasmid,
pcLMP1, was a gift from Tomakazu Yoshizaki. The mutant LMP-1 plasmid,
LMP1–187, was a gift from Nancy Raab-Traub (33). Other LMP-1 serial mutants
were made by PCR and cloning of the corresponding fragments into the
pcDNA3 vector; all the clones were sequenced. mLMP1–231 was made with the
corresponding mutations in a PCR fragment. pQ3-CAT (33 to 5) was made
by cloning the corresponding PCR fragment into pBS-CAT (14). The pQ3M-
CAT plasmid was made in a way similar to the method for pQ2M-CAT by
mutation in the interferon-stimulated response element (ISRE) region (51). The
TRAF1 dominant-negative expression plasmid was a gift from Collin Duckette
(8), and TRAF2 and TRAF3 dominant-negative plasmids were gifts from Nancy
Raab-Traub. The JAK-3 dominant-negative mutant was a gift from John O’Shea
(4). The TRAF5 dominant-negative mutant was made by cloning the C-terminal
amino acids 233 to 557 of TRAF5 into the pcDNA3 vector. The expression of the
FIG. 1. Molecular structure and locations of functional domains in
LMP-1. LMP-1 contains a short cytoplasmic amino terminus, a trans-
membrane hydrophobic domain, and a long cytoplasmic carboxy ter-
minus that contains three major signaling domains. CTAR-1 mediates
interaction with the TRAFs and is the minor NF-B-activating region.
The location of the TRAF-interacting motif, PXQXT, is indicated.
CTAR-2 is the major NF-B-activating region. Also, CTAR-2 can
activate JNK and p38 molecules. Two JAK-3-binding sites are indi-
cated. The JAK-STAT pathway can be activated by the interaction
between JAK-3 and LMP-1. The amino acid numbers are shown. The
drawing is not to scale.
FIG. 2. The LMP-1 TRAF interaction domain is important for
IRF-7 induction. (A) Schematic diagram of LMP-1 mutants. CTAR-1,
CTAR-2, and JAK-3-binding motifs and amino acid numbers are
shown. Solid oval, PXQXT motif. (B) The TRAF interaction domain
in CTAR-1 is responsible for the induction of IRF-7. RPA was per-
formed with IRF-7 and GAPDH probes. Lane 1, yeast RNA; lanes 2
to 7, RNAs from transfected DG75 cells. Lane 2, pcDNA3 transfected;
lane 3, LMP1–200; lane 4, LMP1–212; lane 5, LMP1–231; lane 6,
mLMP1–231. Specific RNA protections are shown. Bottom panel,
short-time exposure for GAPDH-protected areas. A representative
result from three independent experiments is shown. (C) Relative
IRF-7 levels from panel B. Data were obtained by normalizing IRF-7
RNA levels to GAPDH RNA levels with the use of a PhosphorImager.
The column numbers match the lanes in panel B. (D) Western blot
analysis of transfected cells. The Flag antibody, M2, was used for
detection of these LMP-1 mutants. The identity of proteins is indi-
cated. The lane numbers match the lanes in panel B.
12394 ZHANG ET AL. J. VIROL.
TRAF5 fragment was confirmed by Western blot analysis and was confirmed
functionally by inhibition of NF-B activity (data not shown). NF-B expression
plasmids (p65 and p50) and the superrepressor IB (sr-IB) plasmid were gifts
from Albert Baldwin. TRAF5 antibody was purchased from Santa Cruz Biotech-
nology, Inc (sc-6195). LMP-1 monoclonal antibody, CS1–4, was purchased from
Dako. Anti-Flag monoclonal antibody, M2, was purchased from IBI. Tubulin
antibody was purchased from Sigma. Human IRF-3 monoclonal antibody was a
gift from Peter Howley (47).
Western blot analysis with enhanced chemiluminescence. Separation of pro-
teins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed
standard procedures. After the proteins were transferred to a nitrocellulose or
Immobilon membrane, the membrane was blocked with 5% nonfat dry milk in
TBST (50 mM Tris [pH 7.5], 200 mM NaCl, 0.05% Tween 20) at room temper-
ature for 10 min. It was then washed briefly with water and incubated with a
primary antibody in 5% milk in TBST for 1 to 2 h at room temperature or
overnight at 4°C. After a wash with TBST for 10 min three times, the membrane
was incubated with the secondary antibody at room temperature for 1 h. It was
then washed three times with TBST as before, treated with ECL (Amersham) or
SuperSignal (Pierce) detection reagents, and exposed to Kodak XAR-5 film.
Transient transfection, CAT assays, and isolation of transfected cells. For
DG75, 107 cells in 0.5 ml of medium were used for transfection with the use of
a Bio-Rad Gene Pulser (320 V and 925 F). Two days after transfection, cells
were collected for a chloramphenicol acetyltransferase (CAT) assay or for iso-
lation of transfected cells. The CAT and -galactosidase assays were carried out
essentially as described previously (50, 53). The CAT assay results were analyzed
on a Molecular Dynamics PhosphorImager.
For isolation of transfected cells, cells were collected after transfection, and
enrichment for CD4-positive cells was performed with the use of CD4 antibody
conjugated to magnetic beads according to the manufacturer’s recommendation
(Dynal, Inc.). The isolated cells were used for the extraction of total RNA with
the RNease Total RNA Isolation Kit (Qiagen).
RNA extraction and RPA. RNase protection assays (RPA) were performed
with total RNA with the RNase Protection Kit II (Ambion, Inc.). The hybrid-
ization temperature was 53°C or gradient temperatures (49). The human glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) probe was supplied by U.S.
Biochemicals, Inc. The IRF-7 probe was generated with the use of ApaLI-
digested pBS-IRF7A as a template and T7 RNA polymerase. The protected
region consists of nucleotides 1671 to 1890 of IRF-7A (53). This probe cannot
distinguish various splicing forms of IRF-7.
Detection of stabilities of proteins. DG75 and Jijoye cells were treated with
cycloheximide (Sigma) at a concentration of 75 g/ml; cell lysates were made at
various time points. The protein concentration of the lysates was determined,
and Western blot analysis was used to determine the half-lives of proteins with
various specific antibodies.
RESULTS
LMP-1-activated TRAF molecules are involved in the induc-
tion of IRF-7. To test which domain is responsible for the
induction of IRF-7, LMP-1 mutants along with a CD4 expres-
sion plasmid were transiently transfected into DG75 cells, an
EBV-negative cell line, and transfected cells were selected by
the use of CD4 antibody conjugated to magnetic beads (see
Materials and Methods for details). RPA was performed with
total RNAs isolated from transfected cells. As shown in Fig. 2,
results with deletion mutants suggest that CTAR-1 is able to
induce IRF-7 (Fig. 2B, lanes 4 to 7). The efficiency of CTAR-1
for the induction is about 60 to 70% of that of wild-type LMP-1
(compare lanes 5 and 7). Furthermore, the fact that CTAR-1
contributes to induction of IRF-7 RNA suggests that the
PXQXT domain might be important because the domain is the
only one that is currently known in CTAR-1 (7, 31, 41). A
series of LMP-1 mutants within CTAR-1 were generated, as
shown in Fig. 2A. The deletion mutant LMP1–212, which pre-
serves the TRAF interaction domain, was able to induce the
expression of IRF-7; however, LMP1–200 lacks the PXQXT
domain and was unable to induce IRF-7 (Fig. 2B, lanes 9 to 12).
To probe the role of the TRAF interaction domain further,
mLMP1–231, which has point mutations that change the
PXQXT motif into AXAXT, was generated. Genetically, the
association with TRAFs can be destroyed by mutating the
amino acid sequence to AXAXA (PQAA mutation) (7, 31). As
FIG. 3. Dominant-negative mutants of TRAF molecules inhibit the
induction of IRF-7. (A) RPA was performed with IRF-7 and GAPDH
probes with RNAs from transfected DG75 cells. Lane 1, pcDNA3
transfected; lane 2, LMP1–212; lane 3 to 6, LMP1–212 plus
TRAF1DN, TRAF2DN, TRAF3DN, and TRAF5DN, respectively.
Specific protections and undigested probes are shown. Bottom panel,
short-time exposure for GAPDH-protected areas. A representative
result from three independent experiments is shown. (B) Relative
IRF-7 levels from Fig. 3A. Data were obtained by normalizing IRF-7
RNA levels to GAPDH RNA levels with the use of a PhosphorImager.
The column numbers match the lanes in panel A. (C) Western blot
analysis of transfected cells with various antibodies. The identities of
the proteins are indicated. The Flag antibody, M2, was used for de-
tection of LMP1–212. The lane numbers match the lanes in panel A.
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shown in Fig. 2B, mLMP1–231 failed to induce IRF-7 (lane
13). Also, the expression levels of these LMP-1 mutant pro-
teins were approximately the same (Fig. 2D). These data sug-
gest that the TRAF interaction domain is important for the
induction of IRF-7 by LMP-1.
Dominant-negative mutants of TRAFs block the induction
of IRF-7. To examine the involvement of endogenous TRAF
FIG. 4. Two CTARs independently induce the expression of
IRF-7. (A) Schematic diagram of LMP-1 mutants. CTAR-1, CTAR-2,
and JAK-3-binding motifs are indicated. (B) Two CTARs indepen-
dently induce the expression of IRF-7. RPA was performed with IRF-7
and GAPDH probes. Lanes 1, 8, and 12, yeast RNA. Lanes 6 and 7,
undigested GAPDH and IRF-7 probes. In all other lanes, RNAs from
transfected DG75 cells were used. Lanes 2, 9, and 13, pcDNA-3; lane
3, wild-type (wt) LMP-1; lanes 4, 5, 10, and 14, LMP-PQAA; lane 11,
LMPCTAR1; lane 15, LMP-IID; and lane 16, LMP-DM. Specific
RNA protections are shown. Bottom panel, short-time exposure for
GAPDH-protected areas. A representative from three independent
experiments is shown. (C) Relative IRF-7 levels from panel B. Data
were obtained by normalizing IRF-7 RNA levels to GAPDH RNA
levels with the use of a PhosphorImager. The column numbers match
the lanes in panel B. (D) Western blot analysis of transfected cells with
LMP-1 antibody. The lane numbers match the lanes in panel B.
FIG. 5. LMP-DM blocks the induction of IRF-7 by LMP-1. (A)
RPA was performed with IRF-7 and GAPDH probes with RNAs from
transfected DG75 cells. Lane 1, pcDNA3 transfected; lane 2, LMP-1
plus pcDNA3; lanes 3 and 4, LMP-1 plus LMP-DM. The ratio between
LMP-1 and LMP-DM plasmids was 1 to 4. Specific RNA protections
are shown. Bottom panel, short time exposure for GAPDH-protected
areas. A representative result from three independent experiments is
shown. (B) Relative IRF-7 levels from Fig. 5A. Data were obtained by
normalizing IRF-7 RNA levels to GAPDH RNA levels with the use of
a PhosphorImager. The column numbers match the lanes in panel A.
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molecules in the activation of IRF-7, dominant-negative mu-
tants of TRAF (TRAF DNs) were transfected into DG75 cells
along with LMP1–212, and the induction of IRF-7 was exam-
ined. As shown in Fig. 3, the TRAF dominant-negative mu-
tants tested could partially block the induction of endogenous
IRF-7 (lanes 3 to 6). Because the TRAF mutants did not
obviously affect the expression of LMP-1 (Fig. 3C), these data
suggest that the endogenous TRAFs are involved in the induc-
tion of IRF-7.
Two CTARs independently induce the expression of IRF-7.
Although CTAR-1 and the TRAF interaction domain in par-
ticular are involved in the induction of IRF-7, we tested the
role of TRAFs in the context of the whole LMP-1 molecule in
the induction of IRF-7. As shown in Fig. 4B (lanes 3 to 5),
PQAA mutation in intact LMP-1 does not affect the ability of
LMP-1 to induce IRF-7. Also, TRAF dominant-negative mu-
tants cannot block the induction of IRF-7 by the intact LMP-1
molecule (data not shown). These results suggest that the
other region of LMP-1 also is able to induce the expression of
IRF-7. To address the point further, the whole CTAR1 region
was deleted, and the mutant LMP1CTAR1 was transfected
into the cells and tested for induction. As expected,
LMP1CATR1 was able to induce the expression of IRF-7
(Fig. 4B, lane 11). These data strongly indicate that an inde-
pendent signaling pathway(s), other than that derived from
CTAR1, is also able to induce the expression of IRF-7.
To address the possible contribution from the other region
of the LMP-1 molecule, mutations in CTAR2 were made as
shown in Fig. 4A. The tyrosines (Y) in the last three amino
acids of LMP-1 (YYD) have been shown to play an important
role in the signaling pathway of CTAR2; the mutations of
YYD abolish TRADD binding and the activation of NF-B
and AP-1 (11, 21, 25). When these amino acids were mutated
from YYD to IID in the whole LMP-1 molecule, there was no
effect on induction of IRF-7 (Fig. 4B, lane 15), presumably due
to the intact CTAR-1. However, when both CTARs were mu-
tated, the induction of IRF-7 was completely blocked (lane
16). These data indicate that CTAR1 and CTAR2 indepen-
dently induce the expression of IRF-7.
Mutation in both CTARs of LMP-1 has a dominant-negative
effect on induction of IRF-7. Recently there was a report that
mutation in both CTARs resulted in a dominant-negative mu-
tant of LMP-1 (3). Since our LMP-1 mutant in both CTARs
FIG. 6. NF-B is involved in the induction of IRF-7. (A) RPA was
performed with IRF-7 and GAPDH probes. RNAs from transfected
DG75 cells were used. Lanes 1 and 5, pcDNA3 transfected; lane 2,
LMP-1; lane 3, LMP-1 plus sr-IB; lane 4, LMP-1 plus AP1DN. Lane
5, yeast RNA; lane 6, pcDNA3; and lane 7, p65 plus p50 expression
plasmids. Specific RNA protections are shown. Bottom panel, short
time exposure for GAPDH-protected areas. A representative result is
shown. (B) Relative IRF-7 levels from Fig. 4A. Data were obtained by
normalizing IRF-7 RNA levels to GAPDH RNA levels with the use of
a PhosphorImager. The column numbers match the lanes in panel A.
(C) Repression of Qp reporter by NF-B. DG75 cells were transfected
with the Qp reporter constructs, pQ3-CAT (columns 1 and 2), or
pQ3M-CAT (columns 3 and 4), together with pcDNA-3 vector (col-
umns 1 and 3), or with NF-B expression plasmids (p65 plus p50)
(columns 2 and 4). CAT assay results were normalized by -galacto-
sidase activity; Qp CAT activity is expressed relative to the vector
control. Standard deviations are shown.
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(LMP-DM) is similar to the one described in that report, and
because LMP-DM fails to induce IRF-7, we tested whether
LMP-DM could block the induction of IRF-7. As shown in Fig.
5, LMP-1 itself causes the induction of IRF-7 (lane 2). How-
ever, LMP-DM could block the induction of IRF-7 by LMP-1
(lanes 3 and 4), which strongly suggests that CTAR1 and
CTAR2 independently induce the expression of IRF-7 and
that LMP-DM may act as a dominant-negative mutant for
LMP-1, at least in the induction of IRF-7.
NF-B is essential for the induction of IRF-7. The fact that
CTAR1 and CTAR2 independently induce IRF-7 suggests the
existence of a common signaling pathway(s) or molecule(s)
used for induction. LMP-1 CTARs can activate several fre-
quently used signaling molecules with the activation of NF-B
in common. The role of NF-B in the induction of IRF-7 was
examined with the use of a superrepressor IB (sr-IB) plas-
mid. When transfected into the cells along with LMP-1, sr-IB
could significantly repress the endogenous and LMP-1-acti-
vated NF-B activity (data not shown). As shown in Fig. 6,
sr-IB could also block the activation of IRF-7 by LMP-1 (lane
3). In contrast, a dominant-negative mutant for activator pro-
tein 1 (AP1DN) could not (lane 4). AP1DN could block the
activation of an AP-1 reporter construct in transient transfec-
tion assays, indicating that AP1DN was functional (data not
shown). In addition, sr-IB did not obviously affect the expres-
sion levels of LMP-1 (data not shown).
To test the role of NF-B directly, p65 and p50 expression
plasmids were transfected into DG75 cells to generate active
NF-B molecules, and endogenous IRF-7 was measured by
RPA. As shown in Fig. 6, overexpression of NF-B could
induce IRF-7 in DG75 cells. To test whether the induced
IRF-7 was functional, CAT assays were performed with a Qp
reporter construct. IRF-7 represses Qp activity, and as ex-
pected, NF-B could repress Qp (Fig. 6C, column 2). Whether
the repression depended on an intact ISRE element in the Qp
construct was examined. The pQ3M-CAT construct, which has
low but distinct activity, has mutations in the Qp ISRE se-
quence that disrupt the IRF-7–Qp interaction (see Materials
and Methods for details (50, 51). If NF-B inhibits the reporter
activity through IRF-7, then NF-B should not inhibit the
mutated construct. The results showed that NF-B inhibited
Qp through the induction of IRF-7 because the repression
depended on the intact ISRE element in the Qp construct
(column 4). These data indicated that the induced IRF-7 pro-
tein is functional and that NF-B is needed for induction of
IRF-7.
Human IRF-7 protein is a stable protein. It has recently
been reported that IRF-7 is an unstable protein with a half-life
of less than 1 h (42). Because IRF-7 protein levels did not
change obviously during the cell cycle (Zhang, Davenport, and
Pagano, unpublished results), suggesting that IRF-7 is a rela-
tive stable protein, we were interested in examining its half-life.
DG75 and Jijoye cells were treated with cycloheximide, and
cell lysates were made at various time points. Western blot
analysis was used to determine the half-lives of proteins with
various specific antibodies. As shown in Fig. 7, tubulin and
EBNA-1 had very long half-lives, while IRF-1 had a very short
half-life, as expected (5, 43, 46). Because the half-lives of both
EBNA-1 and tubulin are more than 24 h (5, 43), and because
the expression pattern of IRF-7 protein after cycloheximide
block is similar to that of EBNA-1 and tubulin (Fig. 7), the
half-life of IRF-7 protein is probably more than 24 h. Finally,
it should be noted that the IRF-7 protein in Jijoye cells is
mainly active (i.e., phosphorylated and localized in the nucle-
us), whereas in DG75 cells, IRF-7 protein is mainly inactive
(52). Apparently, the phosphorylation status of IRF-7 does not
obviously affect its protein stability. Interestingly, the half-life
of IRF-3 in these two cell lines was very long, similar to IRF-7,
as reported previously (42; also data not shown).
These observations seem to contradict the recent report that
IRF-7 has a very short half-life (0.5 to 1 h) (42). The conflicting
results may be due to the following. (i) Human IRF-7 (hIRF-7)
and mouse IRF-7 (mIRF-7) are different. (ii) The half-life of
mIRF-7 was determined by the use of a hemagglutinin-tagged
IRF-7 construct. The hemagglutinin sequence may affect
mIRF-7 stability. (iii) The cells used to determine the half-life
of mIRF-7 were fibroblasts (42). However, IRF-7 is predomi-
nantly a lymphoid-specific factor (1, 53), and overexpression of
IRF-7 in a nonnative environment might affect its stability.
Here, the half-life of hIRF-7 was determined by examining the
native form in its native environment under physiological con-
centrations. It is possible that degradation of IRF-7s may differ
in different cell types.
DISCUSSION
It is a common phenomenon for a virus to usurp cellular
genes for its own functions. LMP-1 regulates IRF-7 in several
FIG. 7. Human IRF-7 is a stable protein. DG75 and Jijoye cells were treated with cycloheximide (75 g/ml), and cell lysates were made at given
times (hr) after treatment. Western blot analysis with various antibodies was carried out with different parts of the membrane or with the same
membrane with a different antibody after striping of the previous one. More cell lysate from DG75 was used to obtain a level of IRF-7 similar to
that obtained from Jijoye cells. The identities of the proteins are indicated.
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ways, including stimulation of its expression and facilitation of
its phosphorylation and nuclear translocation. By doing so,
LMP-1 uses IRF-7 as a secondary mediator to regulate some
target genes, both cellular and viral, such as those for Tap-2
and Qp-derived EBNA-1 (51–53). Here we have studied the
first steps of this apparently important signal transduction
pathway leading to the induction of IRF-7 by LMP-1.
First, our results provide strong evidence that the two re-
gions (CTARs) of LMP-1 can independently induce the ex-
pression of IRF-7. LMP-1 mutants with a single mutation in
either CTAR that abolishes the function could still induce
IRF-7. Only mutations in both CTARs of LMP-1 (LMP-DM)
led to failure to induce the expression of IRF-7 in transfected
cells (Fig. 4). In addition, LMP-DM, which functions as a
dominant-negative mutant, blocks the induction of IRF-7 by
LMP-1 (Fig. 5). Considering that LMP-1 is an integral mem-
brane protein and depends heavily, if not exclusively, on cel-
lular signaling molecules for its function, the implication from
these results is that IRF-7 might be an important factor for
LMP-1 function and that two independent regions of LMP-1
might be needed, regardless of different cellular environments,
to ensure the induction of IRF-7.
Second, activation of endogenous TRAFs is involved in the
induction of IRF-7: (i) CTAR-1 deletion mutants of LMP-1,
provided they contain the PXQXT motif, are capable of in-
ducing the expression of IRF-7 (Fig. 2 and 3); (ii) mutations in
the PXQXT motif in CTAR-1, which abolish the interaction
with TRAFs, fail to induce IRF-7 (Fig. 3); and (iii) dominant-
negative mutants of TRAFs are capable of blocking the induc-
tion of IRF-7 by CTAR-1 (Fig. 4). These data strongly suggest
that TRAFs are involved in the induction of IRF-7 by LMP-1.
Third, NF-B is an essential factor for the induction of
IRF-7. Coexpression of sr-IB blocked the induction of IRF-7.
Overexpression of NF-B could induce IRF-7 in the same cells
(Fig. 5). Also, the promoter sequence of human IRF-7 is avail-
able in the gene bank, and four consensus NF-B-binding sites
have been identified in a 3-kb fragment directly in front of the
IRF-7 translational initiation codon (data not shown). These
data clearly indicate that active NF-B is necessary for the
induction of IRF-7 by LMP-1. However, activation of endog-
enous NF-B alone apparently is not sufficient to induce
IRF-7. In the Akata Burkitt’s lymphoma cell line, LMP-1 ac-
tivated NF-B, but it could not induce IRF-7 under the same
experimental conditions (51; also data not shown). In DG75
cells, LMP1–231 could induce the expression of IRF-7 (Fig. 2);
however, LMP1–231 did not detectably activate NF-B, pre-
sumably due to the high level of endogenous NF-B activity in
these cells (data not shown). NF-B activation reagents, such
as gamma IFN (IFN-) and tumor necrosis factor alpha, could
not induce IRF-7 in DG75 cells (1, 51; also data not shown).
All these data suggest that NF-B is a necessary but not suf-
ficient factor for the induction of IRF-7.
Interestingly, LMP-1 marginally activated the IRF-7 pro-
moter reporter constructs that contain several NF-B-binding
sites (two- to threefold; data not shown). However, in the same
cells and with the same conditions, LMP-1 strongly induced the
endogenous IRF-7 RNA levels (6- to 10-fold; Fig. 4 to 6).
Because LMP-1 did not obviously affect the stability of IRF-7
RNA (data not shown), one possibility is that the promoter
reporter construct lacks some critical cis-acting element(s).
Another possibility is the chromosomal structure. Because the
major difference between transiently transfected DNA and
endogenous genomic DNA is its structure, LMP-1 may affect
the chromosomal structure that in turn plays an important role
in the activation of IRF-7. To test such a notion, we examined
whether sodium butyrate, a known chromosomal modifier act-
ing through cellular histones (27), could affect the expression
of IRF-7. As shown in Fig. 8, sodium butyrate induces the
expression of IRF-7 in DG75 cells, suggesting that chromo-
somal structure might be involved in the regulation of endog-
enous IRF-7. Sodium butyrate also induced the expression of
IRF-7 in EBV-positive Burkitt’s lymphoma cell lines (data not
shown).
The induction of IRF-7 by IFN- treatment (1, 30, 51)
suggests that the JAK-STAT signaling pathway is important
for the induction of IRF-7. Recently, LMP-1 has been reported
FIG. 8. Sodium butyrate induces the expression of IRF-7. (A) RPA
was performed with IRF-7 and GAPDH probes with RNAs from
DG75 cells. Lane 1, untreated cells; lanes 2 to 4, treatments with 3, 5,
and 10 mM sodium butyrate for 24 h, respectively. Specific RNA
protections are shown. Bottom panel, short-time exposure for
GAPDH-protected areas.
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to interact with JAK-3 molecules and activate STAT-1 (15).
However, a JAK-3 dominant-negative mutant that blocks the
activation of JAKs (4) could not block the induction of IRF-7
by LMP-1 (data not shown). Also, LMP1–231, which lacks the
JAK-3 interaction site, is capable of inducing IRF-7 (Fig. 2).
LMP-DM that retains the intact JAK-3 interaction site is un-
able to induce IRF-7 (Fig. 4). It seems that JAK-3 may not play
a critical role, but at best may play a cooperative role in the
induction of IRF-7 by LMP-1. In sharp contrast, the JAK-
STAT pathway plays a pivotal role in the induction of IRF-7 by
IFN- (29, 30, 42). It is clear that the different inducers use
different signaling molecules for the induction of IRF-7.
In summary, our data provide evidence that two regions of
LMP-1 independently induce IRF-7, which is a secondary me-
diator for the LMP-1 protein in modulating its cellular and
viral functions.
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